Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alzamend Neuro, Inc. - Common Stock (NQ:ALZN)

1.970 -0.010 (-0.51%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 67,456
Open 2.050
Bid (Size) 1.930 (100)
Ask (Size) 1.990 (8,600)
Prev. Close 1.980
Today's Range 1.920 - 2.055
52wk Range 1.690 - 10.35
Shares Outstanding 3,801,604
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
EXCLUSIVE: Alzamend Wraps Clinical Phase Of AL001 Study In Healthy Participants ↗
Alzamend Neuro completed its first Phase 2 trial for AL001, a novel lithium therapy aiming for better brain delivery and safety, reducing the need for drug monitoring. 
Via Benzinga
News headline image
Hewlett Packard Enterprise To Rally Around 33%? Here Are 10 Top Analyst Forecasts For Thursday ↗
 
Via Benzinga

Performance

YTD
+3.7%
+3.7%
1 Month
-15.5%
-15.5%
3 Month
-16.5%
-16.5%
6 Month
-17.9%
-17.9%
1 Year
-80.5%
-80.5%

More News

Read More
News headline image
Alzamend Neuro to Present at the 2025 Military Health System Research Symposium
From Alzamend Neuro, Inc.
Via GlobeNewswire
News headline image
Alzamend Neuro Reports Annual 2025 Financial Results and Provides Update on Clinical Programs
From Alzamend Neuro, Inc.
Via GlobeNewswire
News headline image
Alzamend Neuro Announces Final Closing of $5 Million Private Placement Months Ahead of Schedule
From Alzamend Neuro, Inc.
Via GlobeNewswire
News headline image
Which stocks are experiencing notable movement on Friday? ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
Via Benzinga
News headline image
Top movers in Friday's session ↗
Via Chartmill
News headline image
Traders are paying attention to the gapping stocks in Friday's session. ↗
Via Chartmill
News headline image
Synergy CHC Corp. (NASDAQ: SNYR) Taps Beverage Veteran to Drive FOCUSfactor’s Drink Expansion – More Stocks Inside
Via AB Newswire
Topics Economy
News headline image
Let's take a look at the stocks that are in motion in today's session. ↗
Via Chartmill
News headline image
Alzamend Neuro Stock Rockets On Dosing Of First Human Patient With Lithium-Delivery System AL001 In Phase II Study: Retail’s Thrilled ↗
Via Stocktwits
News headline image
Alzamend Neuro (ALZN) Stock Surges On AL001 Phase II Trial Milestone ↗
Via Benzinga
News headline image
Crude Oil Falls Over 1%; Best Buy Reports Downbeat Results ↗
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
Via Benzinga
News headline image
Keep an eye on the top gainers and losers in Thursday's session. ↗
Via Chartmill
News headline image
The market is filled with gapping stocks in Thursday's session. ↗
Via Chartmill
News headline image
Alzamend Neuro Inc. (NASDAQ: ALZN) Targets Transformative Mental Health Breakthroughs
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Nasdaq Gains Over 1%; Nvidia Posts Strong Revenue ↗
Via Benzinga
BioMedNewsBreaks — Alzamend Neuro, Inc. (NASDAQ: ALZN) Doses First Patient in Phase II Trial for Next-Gen Lithium Therapy AL001
Via Investor Brand Network
News headline image
What's going on in today's pre-market session ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
Via Benzinga
News headline image
Alzamend Neuro Announces Dosing of First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital
From Alzamend Neuro, Inc.
Via GlobeNewswire
News headline image
Alzamend Neuro Enrolls First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital
From Alzamend Neuro, Inc.
Via GlobeNewswire
News headline image
Which stocks are moving before the opening bell on Tuesday? ↗
Via Chartmill

Frequently Asked Questions

Is Alzamend Neuro, Inc. - Common Stock publicly traded?
Yes, Alzamend Neuro, Inc. - Common Stock is publicly traded.
What exchange does Alzamend Neuro, Inc. - Common Stock trade on?
Alzamend Neuro, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Alzamend Neuro, Inc. - Common Stock?
The ticker symbol for Alzamend Neuro, Inc. - Common Stock is ALZN on the Nasdaq Stock Market
What is the current price of Alzamend Neuro, Inc. - Common Stock?
The current price of Alzamend Neuro, Inc. - Common Stock is 1.970
When was Alzamend Neuro, Inc. - Common Stock last traded?
The last trade of Alzamend Neuro, Inc. - Common Stock was at 02/09/26 04:00 PM ET
What is the market capitalization of Alzamend Neuro, Inc. - Common Stock?
The market capitalization of Alzamend Neuro, Inc. - Common Stock is 7.49M
How many shares of Alzamend Neuro, Inc. - Common Stock are outstanding?
Alzamend Neuro, Inc. - Common Stock has 7M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.